KR101909235B1 - Composition for improving skin wrinkle and enhancing elasticity - Google Patents

Abstract

The present invention relates to a composition for improving wrinkles.
2,3,5,4-tetrahydroxydiphenylethylene-2-O-beta-D-glucoside according to the present invention promotes collagen synthesis of fibroblasts of the skin, inhibits collagenase activity, And improving wrinkles, thereby being useful as a pharmaceutical composition, an external preparation for skin, a cosmetic composition or a health food.

Description

Technical Field [0001] The present invention relates to a composition for improving skin wrinkles and enhancing elasticity,

The present invention relates to a composition for improving skin wrinkles and improving elasticity.

Collagen is a major substrate protein produced in fibroblasts of the skin and exists in extracellular epilepsy. Its important functions are mechanical rigidity of skin, resistance of connective tissues and binding force of tissues, support of cell adhesion, division of cells and differentiation Growth or wound healing) are known. Such collagen is reduced by aging and photo aging caused by ultraviolet irradiation, which is known to be closely related to the wrinkling of the skin. Also, in recent years, extensive research on skin aging has developed, and important functions of collagen in skin have been revealed.

In the prior art, there have been products that incorporate collagen into cosmetics from the skin moisturizing effect of collagen, but these cosmetics apply collagen to the skin surface, and since the collagen, which is a polymer, can not be expected to be moisturized by transdermal absorption, Can not be said.

On the other hand, there are known effective substances that promote collagen synthesis and exhibit wrinkle-reducing effects. For example, retinoic acid, transforming growth factor (TGF) [non-patent document 1], animal placenta-derived protein [Patent document 1], betulinic acid [Patent document 2], chlorella extract [ Patent Documents 3 and 4] are known as collagen synthesis promoting substances. However, the above-mentioned effective ingredients are limited in the use amount due to safety problems such as irritation and redness when applied to the skin, or have insufficient effect, so that the effect of improving the skin function by promoting the collagen synthesis of the skin can not be expected. Therefore, there is a desperate need to develop a wrinkle-improving active ingredient that is safe in vivo, stable in its effective component, and most effective than the existing collagen synthesis promoting substance.

Japan Patent No. 8-231370 Japan Patent No. 8-208424 Japan Patent No. 9-40523 Japan Patent No. 10-36283

Cardinale G. et al, Adv. Enzymol., 41, p. 425, 1974

Accordingly, the present inventors have completed the present invention by confirming the effect of improving the elasticity of the skin and improving the wrinkles by promoting the collagen synthesis of the fibroblasts of the skin and inhibiting the collagenase activity :

[Chemical Formula 1]

Accordingly, an object of the present invention is to provide a composition for improving skin wrinkles and elasticity comprising a compound represented by the following formula (1) as an active ingredient:

[Chemical Formula 1]

As means for solving the above problems,

There is provided a pharmaceutical composition for improving skin wrinkles and improving elasticity as an active ingredient comprising a compound represented by the following formula 1:

 [Chemical Formula 1]

As another means for solving the above problems,

A skin external preparation for skin wrinkle improvement and elasticity enhancement comprising a compound represented by the following formula (1) as an active ingredient:

[Chemical Formula 1]

As another means for solving the above problems,

A cosmetic composition for skin wrinkle improvement and elasticity enhancement comprising a compound represented by the following formula (1) as an active ingredient:

[Chemical Formula 1]

As another means for solving the above problems,

A health food for improving skin wrinkles and improving elasticity comprising a compound represented by the following formula (1) as an active ingredient:

[Chemical Formula 1]

2,3,5,4-tetrahydroxydiphenylethylene-2-O-beta-D-glucoside according to the present invention promotes collagen synthesis of fibroblasts of the skin, inhibits collagenase activity, And improves the appearance of wrinkles, thereby being useful for medicines, cosmetics or health foods.

Hereinafter, the configuration of the present invention will be described in detail.

In order to exhibit an excellent skin wrinkle-reducing effect when the skin wrinkle improving ingredient is applied to actual skin, it exhibits a high active wrinkle reducing activity at a low concentration, exhibits excellent ability to penetrate and absorb the skin, And it is preferable that the active ingredient is kept stable on the composition or on the skin, is easy to be formulated into medicines or cosmetics, and is safe for the skin. However, among the known skin wrinkle improving ingredients, the wrinkle improving ingredients that satisfy all of the above characteristics are not common. For example, some wrinkle-improving ingredients have excellent wrinkle-reducing activity even at low concentrations in vitro, but they are difficult to apply to real skin because of their ability to permeate through the skin. Other skin wrinkle-reducing ingredients have low hydrophilicity and are difficult to formulate into medicines or cosmetics. In addition, some skin wrinkle remedies may degrade wrinkles when they are exposed to heat, light, or oxygen, or they may be transformed into other compounds to wrinkle-reducing effects before they are applied to the skin.

As can be seen in the following examples, 2,3,5,4-tetrahydroxydiphenylethylene-2-O-beta-D-glucoside exhibits significantly superior collagenase activity inhibition at low concentrations, and excellent collagen synthesis It can be used as an effective ingredient for medicines, cosmetics, and health food for improving skin wrinkles and elasticity.

Accordingly, the present invention provides a pharmaceutical composition for improving skin wrinkles and improving elasticity comprising a compound represented by the following formula (1) as an active ingredient:

[Chemical Formula 1]

The name of the compound of formula 1 is 2,3,5,4'-Tetrahydroxytoluylene-2-beta-D-glucoside, and the name 2,3,5,4-tetrahydroxydiphenylethylene-2-O- (2,3,5,4-tetrahydoxyldiphenylethylene-2-O-beta-D-glucoside).

The compound of formula (1) may be synthesized or a commercially available compound may be used.

The pharmaceutical composition for improving skin wrinkles and improving the elasticity of the present invention may comprise a pharmaceutically acceptable salt of the compound of formula (1).

The pharmaceutically acceptable salt of the compound of Formula 1 may be an acid addition salt formed using an organic acid or an inorganic acid, and the organic acid may be, for example, formic acid, acetic acid, propionic acid, lactic acid, butyric acid, isobutyric acid, trifluoroacetic acid The organic acid may be selected from the group consisting of hydrochloric acid, hydrobromic acid, hydrochloric acid, hydrobromic acid, hydrobromic acid, hydrobromic acid, hydrobromic acid, hydrobromic acid, malic acid, maleic acid, malonic acid, fumaric acid, succinic acid, monoamide, glutamic acid, tartaric acid, oxalic acid, citric acid, glycolic acid, glucuronic acid, , Benzenesulfonic acid, p-toluenesulfonic acid and methanesulfonic acid-based salts, and the inorganic acid includes, for example, hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, nitric acid, carbonic acid and boric acid-based salts. Preferably in the hydrochloride or acetate form, more preferably in the hydrochloride form.

The above-mentioned acid addition salts may be obtained by a) directly mixing the compound of formula 1 and an acid, or b) dissolving and mixing one of them in a solvent or a water solvent, or c) Lt; RTI ID = 0.0 > acid < / RTI > in a solvent and mixing them.

In addition to the above, additionally saltable forms include, but are not limited to, the salts of gabapentin, pregabalin, nicotinate, adipate, hemimarate, cysteine, acetylcysteine, methionine, arginine, Aspartate and the like.

When the compound of Chemical Formula 1 of the present invention is used as a medicine, it may further contain one or more active ingredients showing the same or similar functions. For example, a known skin wrinkle-improving component or elasticity-enhancing component may be included. When the additional skin wrinkle-improving ingredient and the elasticity-enhancing ingredient whitening ingredient are included, the effect of improving the wrinkle and elasticity of the composition of the present invention may be further enhanced. When the above ingredients are added, skin safety, easiness of formulation, and stability of effective ingredients can be considered according to the combined use. In one embodiment of the present invention, the composition is a wrinkle-improving component known in the art and includes one or more kinds selected from the group consisting of retinoic acid, TGF, protein from animal placenta, betulinic acid and chlorella extract And may further comprise a skin wrinkle improving ingredient. The additional skin wrinkle improving ingredient may be included in an amount of 0.0001 to 10% by weight based on the total weight of the composition, and the content range may include collagen synthesis promoting or collagenase inhibiting activity, skin safety, And the ease of poetry and the like.

In addition, the pharmaceutical composition for improving skin wrinkles and improving elasticity of the present invention may further comprise a pharmaceutically acceptable carrier.

Pharmaceutically acceptable carriers may contain a variety of ingredients such as buffer, injectable sterile water, normal saline or phosphate buffered saline, sucrose, histidine, salts and polysorbates.

The pharmaceutical composition of the present invention can be administered orally or parenterally, and can be administered in the form of a general pharmaceutical preparation, for example, various forms of oral and parenteral administration at the time of clinical administration. In the case of formulation, , An extender, a binder, a wetting agent, a disintegrant, a surfactant, and the like.

Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may be prepared by mixing the pharmaceutical composition of the present invention with at least one excipient such as starch, calcium carbonate, Sucrose, lactose, gelatin, and the like.

In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Examples of liquid formulations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used.

Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used as the non-aqueous solvent and suspension agent. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.

In the present invention, "wrinkle improvement" refers to inhibiting or inhibiting the generation of wrinkles on the skin, or alleviating the wrinkles already generated.

The pharmaceutical composition of the present invention can provide a desirable wrinkle-improving effect and elasticity-enhancing effect when an effective amount of the compound of Formula 1 is included. In the present invention, the term "effective amount" refers to the amount of a compound capable of inhibiting or inhibiting the generation of wrinkles of the skin or alleviating the wrinkles already formed. An effective amount of the compound of formula (1) contained in the composition of the present invention will vary depending on the form in which the composition is commercialized, how the compound is applied to the skin, and the time on the skin. For example, when the composition is commercialized as a medicament for dermatological treatment due to wrinkle formation, elasticity reduction, and stain on the skin, the compound of formula 1 may be added at a higher concentration than the case where it is commercialized as a cosmetic product applied to the skin. . Accordingly, the daily dosage is 0.1 to 100 mg / kg, preferably 30 to 80 mg / kg, more preferably 50 to 60 mg / kg, based on the amount of the compound of formula (1) 6 times a day.

The pharmaceutical composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers.

The present invention can also be provided as a formulation for external skin application for skin wrinkle improvement and elasticity enhancement comprising the compound of formula (1) as an active ingredient.

When the compound of formula (1) is used as an external preparation for skin, it may further comprise at least one selected from the group consisting of fatty substances, organic solvents, solubilizers, thickeners and gelling agents, softeners, antioxidants, suspending agents, stabilizers, foaming agents, , Water, ionic or nonionic emulsifiers, fillers, sequestering agents and chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or external preparations for skin And any other ingredients used in the skin sciences. The components can also be introduced in amounts commonly used in the field of dermatology.

When the compound of Formula 1 is provided as an external preparation for skin, it may have a formulation such as, but not limited to, ointments, patches, gels, creams or sprays.

The present invention can also provide a cosmetic composition for improving skin wrinkles and improving elasticity comprising the compound of Formula 1 as an active ingredient.

When the compound of Chemical Formula 1 is used as a cosmetic, the cosmetic product containing the compound of Chemical Formula 1 as an active ingredient may be prepared in the form of a general emulsified formulation and a solubilized formulation. For example, creams, essences, cosmetic creams, sprays, gels, packs, sunscreens, make-up bases, liquids such as lotions such as lotion, facial lotion, body lotion, A powder, a cleansing lotion, a makeup removing agent such as a cleansing oil, a cleaning agent such as a cleansing foam, a soap, a body wash and the like.

The cosmetic composition may further contain, in addition to the compound of Formula 1, a lipid, an organic solvent, a solubilizing agent, a thickening agent and a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, , Ionic or nonionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, barrier agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or cosmetics And may contain adjuvants commonly used in the cosmetics field, such as any of the other ingredients.

In the case of a wash-off type cosmetic such as a make-up removing agent, a detergent, etc. in which the active ingredient remains on the skin in a short period of time when the compound of formula (1) is produced into a cosmetic product, . On the other hand, in the case of leave-on type cosmetics, such as lotion, cream, essence, etc., in which the active ingredient remains on the skin for a long period of time, It may be included. In one embodiment of the present invention, although not limited thereto, the composition may contain 0.0001 wt% to 10 wt% (preferably 0.0001 wt% to 1 wt%) of the compound of Formula 1 based on the total weight of the composition . When the composition of the present invention contains less than 0.0001% by weight of the compound of formula (I), sufficient wrinkle improvement and elasticity improvement effect can not be expected. When the composition contains more than 10% by weight, This is to prevent skin safety problems.

The present invention also relates to a health food for improving skin wrinkles and improving elasticity comprising the compound of formula (1).

Herein, the term "health food" means a food prepared by adding the compound of formula (1) to food materials such as beverage, tea, spice, gum and confectionery, or by encapsulation, powdering or suspension, But it has the advantage that there are no side effects that can occur when a drug is used for a long period of time using a food as a raw material.

Since the health food of the present invention thus obtained can be ingested on a daily basis, it can be expected to have a high skin wrinkle improvement and an elasticity increasing effect, which is very useful.

When the compound of Chemical Formula 1 is used as a food additive, the compound of Chemical Formula 1 may be added as it is or may be used together with other food or food ingredients, and may be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to its intended use (prevention, health or therapeutic treatment). Generally, the composition of the present invention is added in an amount of not more than 15 parts by weight, preferably not more than 10 parts by weight, based on the raw material, when the food or beverage is produced. However, in the case of long-term consumption intended for health and hygiene purposes or for health control purposes, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range .

There is no particular limitation on the kind of the food. Examples of the food to which the above substance can be added include dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, Alcoholic beverages, and vitamin complexes, all of which include healthy foods in a conventional sense.

The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Such natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the composition of the present invention.

In addition to the above, the health food of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acids and salts thereof, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, , A carbonating agent used in carbonated drinks, and the like. In addition, the health food of the present invention may contain flesh for the production of natural fruit juice, fruit juice drink and vegetable drink. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

Hereinafter, the present invention will be described in detail by way of examples. However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.

Reference Example 1: Preparation of 2,3,5,4-tetrahydoxyldiphenylethylene-2-O-beta-D-glucoside (2,3,5,4-tetrahydrodiphenylethylene- Information

2,3,5,4'-Tetrahydroxytoluylene-2-beta-D-glucoside

CAS No .: 55327-45-2

Origin and Sink: Fallopia multiflora

Example  1: Collagen synthesis effect

The substances of Table 1 below were added to the culture medium of human-derived fibroblasts to examine the promoting effect of collagen synthesis at the cellular level.

The synthesized collagen was quantitated using a PICP EIA kit (Procollagen Type I C-Peptide Enzyme Immunoassay Kit). To evaluate the cytotoxicity of human fibroblasts before experimentation at concentrations of 10 ppm, 1 ppm, 0.1 ppm, 0.01 ppm, and 0.001 ppm of the test substance (method for MTT test by culturing fibroblasts [Reference: Mossman T. ). Rapid Colorimetric Assay for Cellular Growth & Survival: Application to proliferation & cytotoxicity assays. Journal of Immunological Methods 65, 55-63].

In the experiment, the final concentrations of 2,3,5,4-tetrahydroxydiphenylethylene-2-O-beta-D-glucoside were 1 ppm and 10 ppm, and each sample was added to the culture medium of human fibroblasts After culturing for 1 day, the culture was taken and the degree of collagen synthesis at each concentration was measured at 450 nm using a PICP EIA kit using a spectrophotometer. For the comparison of the effects, the degree of collagen synthesis was measured by the same method for the culture medium of fibroblasts (control group) to which nothing had been added and the sample added with vitamin C to a final concentration of 52.8 / / ml. The amount of collagen production was measured as the UV absorbance, and the increase rate of collagen production was calculated as a relative ratio of collagen production to the control. The results are summarized in Table 1 below.

Effect of collagen biosynthesis of 2,3,5,4-tetrahydroxydiphenylethylene-2-O-beta-D-glucoside (number of repeats = 4) sample Absorbance Absorbance average Collagen growth rate (%) 2,3,5,4-tetrahydroxydiphenylethylene-2-O-beta-D-glucoside
10 ppm 379.057 339.14 112.30 326.818 344.808 305.878 2,3,5,4-tetrahydroxydiphenylethylene-2-O-beta-D-glucoside
1 ppm 309.401 307.47 101.81 307.878 302.294 310.309 Control group
(No additives) 302 302 - Vitamin C
52.8 / / ml 407 407 134.77

As can be seen from the results of Table 1 above, 2,3,5,4-tetrahydroxydiphenylethylene-2-O-beta-D-glucoside is generally more effective than vitamin C, Collagen synthesis effect was demonstrated at low concentration.

Example  2: Collagenase  Activity inhibitory effect

The collagenase inhibitory effect of the substances shown in Table 2 was confirmed as follows.

To evaluate the cytotoxicity of human fibroblasts before experimentation at concentrations of 10 ppm, 1 ppm, 0.1 ppm, 0.01 ppm, and 0.001 ppm of the test substance (method for MTT test by culturing fibroblasts [Reference: Mossman T. ). Rapid Colorimetric Assay for Cellular Growth & Survival: Application to proliferation & cytotoxicity assays. Journal of Immunological Methods 65, 55-63].

Human normal skin cells, fibroblasts, were inoculated into 24-well microplates at 2.5 × 10 ⁴ cells per well, cultured in 10% serum DMEM medium and 37 ° C. for 24 hours, and 10% serum DMEM medium was removed , Washed once with phosphate buffered saline, and incubated with serum-free DMEM medium supplemented with 2,3,5,4-tetrahydroxydiphenylethylene-2-O-beta-D-glucoside, And further incubated for 30 min in serum-free DMEM medium without 4-tetrahydroxydiphenylethylene-2-O-beta-D-glucoside.

After 30 minutes of sample treatment, the cells were incubated for 24 hours with 50 ng / ml TNF-alpha (tumor necrosis factor-alpha), a substance known to produce MMP-1.

At this time, the TNF-α-untreated group and the treated group showed no TNF-α-treated group in the control group without 2,3,5,4-tetrahydroxydiphenylethylene-2-O- Treated group and TNF-α treated group.

The supernatant of each well was collected and the amount (ng / ml) of newly synthesized MMP-1 was measured using an MMP-1 assay kit (Amersham, USA). The inhibition rate of collagenase activity was determined by MMP -1 production inhibition rate (%) was calculated, and the results are shown in Table 2 below.

The amount of MMP-1 in the control group refers to the amount of MMP-1 in the TNF-treated group, and the amount of MMP-1 in the test group refers to the group to which the substance is added at each concentration.

[Equation 1]

Inhibitory effect of 2,3,5,4-tetrahydroxydiphenylethylene-2-O-beta-D-glucoside on collagenase activity (number of repeats = 4) sample The amount of MMP-1 (ng / ml) Inhibition rate (%) 2,3,5,4-tetrahydroxydiphenylethylene-2-O-beta-D-glucoside 10 ppm 3.87 74.53 2,3,5,4-tetrahydroxydiphenylethylene-2-O-beta-D-glucoside 1 ppm 12.73 16.14 Negative control (TNF untreated) 3.27 - The positive control (TNF treatment) 15.18 -

Formulation example  1: Preparation of pharmaceutical preparations

1. Manufacturing of powder

0.001 g of the compound of formula (1)

Lactose 1g

The above components were mixed and packed in airtight bags to prepare powders.

2. Preparation of tablets

0.2 mg of the compound of formula (1)

100 mg of corn starch

100 mg of milk

Stearic acid  Magnesium 2 mg

After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.

3. Preparation of capsules

0.2 mg of the compound of formula (1)

100 mg of corn starch

100 mg of milk

Stearic acid  Magnesium 2 mg

After mixing the above components, the capsules were filled in gelatin capsules according to the conventional preparation method of capsules.

4. Manufacture of rings

0.003 g of the compound of formula (1)

Lactose 1.5 g

Glycerin 1 g

Xylitol  0.5 g

After mixing the above components, they were prepared so as to be 4 g per one ring according to a conventional method.

5. Manufacture of granules

2 mg of the compound of formula (1)

Soybean extract 50 mg

200 mg of glucose

600 mg of starch

After mixing the above components, 100 mg of 30% ethanol was added and dried at 60 캜 to form granules, which were then filled in a capsule.

Formulation example  2: Manufacture of cosmetics

1. Manufacture of softening longevity (skin lotion)

As the following composition, the number of softening times containing the compound of formula (1) as an active ingredient was prepared according to a conventional method.

0.1% by weight of the compound of formula (1)

Beta-1,3-glucan 1.0 wt%

Butylene glycol 2.0 wt%

Propylene glycol 2.0 wt%

Carboxyvinyl polymer 0.1 wt%

0.2% by weight of phage-12 nonylphenyl ether

Polysorbate 80 0.4 wt%

Ethanol 10.0 wt%

0.1% by weight triethanolamine

Preservative 0.05 wt%

0.05% by weight of pigment

0.05% by weight fragrance

Purified water to 100%

2. Manufacture of nutrition lotion (milk lotion)

As in the following composition, a nutritional lotion containing the compound of the formula (1) as an active ingredient was prepared by a conventional method.

0.1% by weight of the compound of formula (1)

Beta-1,3-glucan 1.0 wt%

4.0 wt%

Polysorbate 60 1.5 wt%

1.5% by weight of sorbitan sesquioleate

0.5% by weight liquid paraffin

Caprylic / capric triglyceride 5.0 wt%

Glycerin 3.0 wt%

3.0% by weight of butylene glycol

3.0% by weight of propylene glycol

Carboxyvinyl polymer 0.1 wt%

0.2% by weight triethanolamine

Preservative 0.05 wt%

0.05% by weight of pigment

0.05% by weight fragrance

Purified water to 100%

3. Manufacture of nutritional cream

A nutritional cream containing the compound of formula (1) as an active ingredient was prepared according to a conventional method, as shown below.

0.2% by weight of the compound of formula (1)

Beta-1,3-glucan 5.0 wt%

Wax 10.0 wt%

Polysorbate 60 1.5 wt%

≪ tb > < tb > < tb >

0.5% by weight of sorbitan sesquioleate

Liquid paraffin 10.0 wt%

Squalane 5.0 wt%

Caprylic / capric triglyceride 5.0 wt%

Glycerin 5.0 wt%

3.0% by weight of butylene glycol

3.0% by weight of propylene glycol

0.2% by weight triethanolamine

Preservative 0.05 wt%

0.05% by weight of pigment

0.05% by weight fragrance

Purified water to 100%

4. Manufacture of massage cream

A massage cream containing the compound of formula (I) as an active ingredient was prepared according to a conventional method, as shown below.

0.1% by weight of the compound of formula (1)

Beta-1,3-glucan 3.0 wt%

Wax 10.0 wt%

Polysorbate 60 1.5 wt%

≪ tb > < tb > < tb >

0.8% by weight of sorbitan sesquioleate

Liquid paraffin 40.0 wt%

Squalane 5.0 wt%

Caprylic / capric triglyceride 4.0 wt%

Glycerin 5.0 wt%

3.0% by weight of butylene glycol

3.0% by weight of propylene glycol

0.2% by weight triethanolamine

Preservative 0.05 wt%

0.05% by weight of pigment

0.05% by weight fragrance

Purified water to 100%

5. Manufacture of pack

A pack containing the compound of formula (1) as an active ingredient was prepared according to a conventional method, as shown below.

0.2% by weight of the compound of formula (1)

Beta-1,3-glucan 1.0 wt%

Polyvinyl alcohol 13.0 wt%

0.2% by weight of sodium carboxymethylcellulose,

Glycerin 5.0 wt%

Allantoin 0.1 wt%

6.0% by weight of ethanol

0.3% by weight of phage-12 nonylphenyl ether

Polysorbate 60 0.3 wt%

Preservative 0.05 wt%

0.05% by weight of pigment

0.05% by weight fragrance

Purified water to 100%

Formulation example  3: Topical  Produce

1. Manufacture of gel

As in the following composition, a gel containing the compound of formula (1) as an active ingredient was prepared according to a conventional method.

0.1% by weight of the compound of formula (1)

0.1% by weight of beta-1,3-glucan

0.05% by weight of sodium ethylenediaminetetraacetate

Glycerin 5.0 wt%

Carboxyvinyl polymer 0.3 wt%

5.0% by weight of ethanol

≪ tb > < tb > < tb >

Triethanolamine 0.3 wt%

Preservative 0.05 wt%

0.05% by weight of pigment

0.05% by weight fragrance

Purified water to 100%

2. Manufacture of ointment

An ointment containing the compound of formula (I) as an active ingredient was prepared according to a conventional method, as shown below.

0.5% by weight of the compound of formula (1)

Beta-1,3-glucan 10.0 wt%

Wax 10.0 wt%

Polysorbate 60 5.0 wt%

≪ tb > < tb > < tb >

0.5% by weight of sorbitan sesquioleate

Vaseline 5.0 wt%

Liquid paraffin 10.0 wt%

Squalane 5.0 wt%

SHARE BUTTER 3.0 wt%

Caprylic / capric triglyceride 5.0 wt%

Glycerin 10.0 wt%

Propylene glycol 10.2 wt%

0.2% by weight triethanolamine

Preservative 0.05 wt%

0.05% by weight of pigment

0.05% by weight fragrance

Purified water to 100%

3. Preparation of topical medicament (gel ointment)

A gel ointment agent containing the compound of the formula (1) as an active ingredient was prepared according to a conventional method.

0.5% by weight of the compound of formula (1)

Beta-1,3-glucan 10.0 wt%

1.5% by weight of polyacrylic acid (Carbopol 940)

5.0% by weight of isopropanol

Hexylene glycol 25.0 wt%

Triethanolamine 1.7 wt%

Deionized water to 100%

4. Preparation of topical medicines (patches)

As the following composition, a patch containing a compound of the formula (1) as an active ingredient was prepared by a conventional method.

0.5% by weight of the compound of formula (1)

Beta-1,3-glucan 3.0 wt%

Hexylene glycol 20.0 wt%

Diethylamine 0.7 wt%

1.0% by weight of polyacrylic acid (Carbopol 934P)

0.1% by weight of sodium sulfite

1.0% by weight of polyoxyethylene lauryl ether (E.O. = 9)

1.0% by weight of polyhydroxyethylene cetyl stearyl ether (Cetomacrogol 1000)

Viscous paraffin oil 2.5 wt%

2.5% by weight of caprylic acid ester / capric acid ester (Cetiol LC)

Polyethylene glycol 400 3.0 wt%

Deionized water to 100%

Formulation example  4: Manufacturing of food

Foods containing the compound of formula (I) of the present invention were prepared as follows.

1. Manufacture of Flour Food

0.05 to 1.0 part by weight of the compound of Formula 1 was added to wheat flour, and a bread, a cake, a cookie, a cracker and a noodle were prepared using the mixture to prepare a health food.

2. Manufacture of dairy products

0.2 part by weight of the compound of Formula 1 was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.

3. Manufacturing of wire

Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and the mixture was granulated to a powder having a particle size of 60 mesh. Black soybeans, black sesame seeds, and perilla seeds were steamed and dried by a conventional method, and then they were prepared into powder having a particle size of 60 mesh by a pulverizer. The compound of Formula 1 was concentrated under reduced pressure in a vacuum concentrator, sprayed, and dried with a hot-air drier, and the resulting dried product was pulverized to a size of 60 mesh with a pulverizer to obtain a dried powder.

The grains, seeds, and dry powder of the compound of formula (1) prepared above were blended in the following proportions relative to 100 parts by weight of the mixed powder.

(30 parts by weight of brown rice, 15 parts by weight of yulmu, 20 parts by weight of barley)

Seeds (7 parts by weight of perilla, 8 parts by weight of black beans, 7 parts by weight of black sesame seeds)

(1) (0.1 part by weight),

(0.5 part by weight),

Rhubarb (0.5 Weight portion )

Formulation example  5: Manufacture of beverages

1. Manufacture of health drinks

0.1 mg of the compound of formula (1)

Citric acid 1000 mg

100 g of oligosaccharide

Plum concentrate 2 g

Taurine 1 g

Purified water  All 900 mL

The above components were mixed according to a conventional health drink manufacturing method, and the mixture was heated at 85 DEG C for about 1 hour with stirring. Then, the solution thus prepared was filtered and sterilized in a sterilized 2L-container, Lt; RTI ID = 0.0 > health < / RTI >

Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the blending ratio may be arbitrarily varied according to the regional and national preferences such as the demand level, the demanding country, and the intended use.

2. Manufacture of vegetable juice

1 g of the compound of formula (I) of the present invention was added to 1,000 mL of tomato or carrot juice to prepare vegetable juice for health promotion.

3. Manufacture of fruit juice

1 g of the compound of formula (1) was added to 1,000 mL of apple or grape juice to prepare fruit juice for health promotion.

Claims (10)

A pharmaceutical composition for improving skin wrinkles and improving elasticity comprising a compound represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]

The method according to claim 1,
Wherein the active ingredient is contained in an amount of 0.0001% by weight to 10% by weight based on the total composition.
An external skin preparation for improving skin wrinkles and improving elasticity comprising a compound represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]

The method of claim 3,
Wherein the external preparation is a formulation of ointment, patch, gel, cream or spray.
The method according to claim 1,
Wherein the active ingredient is contained in an amount of 0.0001% by weight to 10% by weight relative to the total composition.
A cosmetic composition for improving skin wrinkles and improving elasticity comprising a compound represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]

The method according to claim 6,
Cosmetics, essences, lotions, creams, packs, gels, powders, foundations or detergents.
The method according to claim 6,
Wherein the active ingredient is contained in an amount of 0.0001% by weight to 10% by weight based on the total composition.
A health food for improving skin wrinkles and improving elasticity comprising a compound represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]

10. The method of claim 9,
Wherein the active ingredient is contained in an amount of 0.0001 to 10% by weight based on the whole composition.